Project Grant R01CA278908
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$578K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award, with an ID of R01CA294704, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for the project "Radiation and Dendritic Cell Combination to Improve Immunotherapy Response in Intrahepatic Cholangiocarcinoma". The $610,890 award, effective September 1, 2024 through August 31, 2029, will support a two-part research study. The first aim is to assess the clinical efficacy of combining external beam...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This Project Grant award of $662,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate how fractionated radiation therapy affects the tumor microenvironment and influences drug delivery for more effective chemoradiotherapy. The project aims to: 1) quantify how local radiation reshapes the tumor microenvironment to impact passive drug delivery in...
This $1,224,644 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to dissect a novel tumor-promoting axis involving the immune checkpoint protein B7-H4 in intrahepatic cholangiocarcinoma (CCA), a highly desmoplastic and deadly form of bile duct cancer. The 5-year award, effective August 2024, will leverage the awardee's (Icahn School of Medicine at Mount Sinai) expertise and preliminary data to: 1) elucidate the molecular...
This $585,976 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to enhance the efficacy of radiation therapy by spatially restricting anti-TGFβ treatment to the tumor microenvironment. The project aims to determine the role of self-renewing stem-like CD8+ T cells in local and distant radiation response, and to test a combination therapy of radiation with spatially restricted TGFβ inhibition to preserve these critical...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on the role of CD91-mediated signaling in cancer immunosurveillance. The research aims to develop a new mouse model to test the importance of CD91 signaling in response to tumor-derived heat shock proteins (HSPs) for priming T cell responses against nascent, emerging tumors. The goal is to better understand the mechanisms by...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will provide $713,601 in funding over a 5-year period from August 1, 2025 to July 31, 2030. The project aims to characterize the mechanisms by which defects in the homologous recombination (HR) DNA repair pathway influence the efficacy of immune checkpoint blockade (ICB) therapies in cancer treatment....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,419,108 to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The award will fund research to gain insights into how blocking the SEMA4D signaling pathway, when combined with immune checkpoint blockade, enhances the activity of antigen-presenting dendritic...